Artículos por temáticas

Parkinson disease: Truncated α-synuclein causes mitochondrial toxicity.

Ridler C.

Nat Rev Neurol. 2018 Mar 16. doi: 10.1038/nrneurol.2018.33. [Epub ahead of print] No abstract available.

Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia.

Beck RB, McGovern EM, Butler JS, Birsanu D, Quinlivan B, Beiser I, Narasimham S, O'Riordan S, Hutchinson M, Reilly RB.

J Vis Exp. 2018 Jan 27;(131). doi: 10.3791/56310.

Entrainment for attentional selection in Parkinson's disease.

Te Woerd ES, Oostenveld R, de Lange FP, Praamstra P.

Cortex. 2018 Feb;99:166-178. doi: 10.1016/j.cortex.2017.11.011. Epub 2017 Nov 26.

Autoimmune and paraneoplastic movement disorders: An update.

Baizabal-Carvallo JF, Jankovic J.

J Neurol Sci. 2018 Feb 15;385:175-184. doi: 10.1016/j.jns.2017.12.035. Epub 2017 Dec 30. Review.

Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease.

Gaare JJ, Nido GS, Sztromwasser P, Knappskog PM, Dahl O, Lund-Johansen M, Maple-Grødem J, Alves G, Tysnes OB, Johansson S, Haugarvoll K, Tzoulis C.

Mov Disord. 2018 Sep 5. doi: 10.1002/mds.64. [Epub ahead of print]

Chaperone-mediated autophagy as a therapeutic target for Parkinson disease.

Campbell P, Morris H, Schapira A.

Expert Opin Ther Targets. 2018 Sep 10:1-10. doi: 10.1080/14728222.2018.1517156. [Epub ahead of print]

Luminance Changes Drive Directional Startle through a Thalamic Pathway.

Heap LAL, Vanwalleghem G, Thompson AW, Favre-Bulle IA, Scott EK.

Neuron. 2018 Jul 25;99(2):293-301.e4. doi: 10.1016/j.neuron.2018.06.013. Epub 2018 Jul 5.

Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.

Chen HH, Chang PC, Chen C, Chan MH.

Pharmacol Rep. 2018 Aug;70(4):668-676. doi: 10.1016/j.pharep.2018.01.003. Epub 2018 Jan 12.

Biallelic Mutations in ADPRHL2, Encoding ADP-Ribosylhydrolase 3, Lead to a Degenerative Pediatric Stress-Induced Epileptic Ataxia Syndrome.

Ghosh SG, Becker K, Huang H, Salazar TD, Chai G, Salpietro V, Al-Gazali L, Waisfisz Q, Wang H, Vaux KK, Stanley V, Manole A, Akpulat U, Weiss MM, Efthymiou S, Hanna MG, Minetti C, Striano P, Pisciotta

Am J Hum Genet. 2018 Jul 25. pii: S0002-9297(18)30237-4. doi: 10.1016/j.ajhg.2018.07.010. [Epub ahead of print]

Voice quality severity and responsiveness to levodopa in Parkinson's disease.

Cushnie-Sparrow D, Adams S, Abeyesekera A, Pieterman M, Gilmore G, Jog M.

J Commun Disord. 2018 Jul 22;76:1-10. doi: 10.1016/j.jcomdis.2018.07.003. [Epub ahead of print]

Bioinformatic analysis for the identification of key candidate genes and pathways in the substantia nigra in Parkinson's disease.

Liu H, Huang Y, Li J.

J Integr Neurosci. 2018 Jul 13. doi: 10.3233/JIN-180091. [Epub ahead of print]

Inflammatory bowel disease and risk of Parkinson's disease in medicare beneficiaries.

Camacho-Soto A, Searles Nielsen S, Racette BA.

Parkinsonism Relat Disord. 2018 Dec;57:77. doi: 10.1016/j.parkreldis.2018.06.028. Epub 2018 Jun 27. No abstract available.

Self-report data as a tool for subtype identification in genetically-defined Parkinson's Disease.

Winslow AR, Hyde CL, Wilk JB, Eriksson N, Cannon P, Miller MR, Hirst WD.

Sci Rep. 2018 Aug 28;8(1):12992. doi: 10.1038/s41598-018-30843-6.

Chemosensory perception is specifically impaired in Parkinson's disease.

Tremblay C, Durand Martel P, Frasnelli J.

Parkinsonism Relat Disord. 2018 Aug 6. pii: S1353-8020(18)30332-8. doi: 10.1016/j.parkreldis.2018.08.002. [Epub ahead of print]

Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.

Ryden LE, Lewis SJG.

Drugs Aging. 2018 Dec 17. doi: 10.1007/s40266-018-0624-5. [Epub ahead of print]